FDA-cleared profile

cvi42 Software Application

Circle Cardiovascular Imaging Inc. · CT/CTA; MRI · FDA-cleared (510(k))

Authorized purpose: View, post-process, and qualitatively and quantitatively evaluate cardiovascular MR and CT images in DICOM format to obtain diagnostic information as part of a comprehensive diagnostic decision-making process.

Clinical role
Post-acquisition viewing and post-processing with qualitative and quantitative measurement, semi-automatic segmentation, calcium scoring, vessel analysis, and reporting for clinician-led diagnostic review.
Images and patients
CT/CTA; MRI · Cardiovascular system; heart, coronary and adjacent vessels, and cardiac valves
Key limitation
Keep in mind: The device must not be used to view or analyze non-cardiac body parts. The semi-automated machine-learning modules are intended for adults. Results support a comprehensive physician decision process and do not replace clinician review. The packet reports no clinical study was necessary for substantial equivalence; module-specific validation results are not a global diagnostic-performance claim.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: View, post-process, and qualitatively and quantitatively evaluate cardiovascular MR and CT images in DICOM format to obtain diagnostic information as part of a comprehensive diagnostic decision-making process.
  • Which images or clinical context are in scope?Modality: CT/CTA; MRI Anatomy or clinical context: Cardiovascular system; heart, coronary and adjacent vessels, and cardiac valves Input: Previously acquired cardiovascular MR and CT images in DICOM format from cardiovascular MR or CT scanners; the packet limits analysis to cardiac images and states that the machine-learning modules are intended for adults.
  • Who uses it?Intended users: Qualified medical professionals experienced in examining and evaluating cardiovascular MR or CT images.
  • What does the software produce?Output: Display and reconstruction tools plus measurements including distance, area, volume, mass, signal intensity, Agatston score, stenosis, velocity, strain, cardiac function metrics, and semi-automatic cardiac segmentation; also calcium scoring, coronary centerline analysis, vessel stenosis evaluation, lesion reporting, and key images.
  • What is its most important limitation?Key limitation: The device must not be used to view or analyze non-cardiac body parts. The semi-automated machine-learning modules are intended for adults. Results support a comprehensive physician decision process and do not replace clinician review. The packet reports no clinical study was necessary for substantial equivalence; module-specific validation results are not a global diagnostic-performance claim.

Clinical takeaway. Clinical role: View, post-process, and qualitatively and quantitatively evaluate cardiovascular MR and CT images in DICOM format to obtain diagnostic information as part of a comprehensive diagnostic decision-making process.

Evidence takeaway. Evidence from the reviewed source record: FDA verification and validation covered non-ML outputs and machine-learning modules. Validation used 235 anonymized patient images with component-specific counts: 70 coronary, 102 calcium, 63 SAX function, 63 each for 2-, 3-, and 4-chamber LAX function, and 252 function-classification samples. Reported ranges were 97%-100% series classification, 7%-10% SAX and 5%-9% LAX volumetric MAE, 86%-99% calcium classification, 82%-94% coronary centerline performance, and 98%-100% coronary-mask performance. Cardiac CT segmentation reported LV MAE below 10%, Dice above 86%, Hausdorff distance below 9.5 mm, and EF bias 1.3% (95% CI -12 to 14); RV MAE below 18%, Dice above 85%, Hausdorff distance below 18 mm, and EF bias -5.5% (95% CI -15 to 4.4); LV-myocardium MAE below 17%, Dice above 82%, and Hausdorff distance below 15 mm.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
View, post-process, and qualitatively and quantitatively evaluate cardiovascular MR and CT images in DICOM format to obtain diagnostic information as part of a comprehensive diagnostic decision-making process.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Post-acquisition viewing and post-processing with qualitative and quantitative measurement, semi-automatic segmentation, calcium scoring, vessel analysis, and reporting for clinician-led diagnostic review.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Previously acquired cardiovascular MR and CT images in DICOM format from cardiovascular MR or CT scanners; the packet limits analysis to cardiac images and states that the machine-learning modules are intended for adults.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Display and reconstruction tools plus measurements including distance, area, volume, mass, signal intensity, Agatston score, stenosis, velocity, strain, cardiac function metrics, and semi-automatic cardiac segmentation; also calcium scoring, coronary centerline analysis, vessel stenosis evaluation, lesion reporting, and key images.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Clinical cardiovascular imaging workflow; the FDA packet permits stand-alone or networked use but does not specify a facility type.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Qualified medical professionals experienced in examining and evaluating cardiovascular MR or CT images.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
The device must not be used to view or analyze non-cardiac body parts. The semi-automated machine-learning modules are intended for adults. Results support a comprehensive physician decision process and do not replace clinician review. The packet reports no clinical study was necessary for substantial equivalence; module-specific validation results are not a global diagnostic-performance claim.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA verification and validation covered non-ML outputs and machine-learning modules. Validation used 235 anonymized patient images with component-specific counts: 70 coronary, 102 calcium, 63 SAX function, 63 each for 2-, 3-, and 4-chamber LAX function, and 252 function-classification samples. Reported ranges were 97%-100% series classification, 7%-10% SAX and 5%-9% LAX volumetric MAE, 86%-99% calcium classification, 82%-94% coronary centerline performance, and 98%-100% coronary-mask performance. Cardiac CT segmentation reported LV MAE below 10%, Dice above 86%, Hausdorff distance below 9.5 mm, and EF bias 1.3% (95% CI -12 to 14); RV MAE below 18%, Dice above 85%, Hausdorff distance below 18 mm, and EF bias -5.5% (95% CI -15 to 4.4); LV-myocardium MAE below 17%, Dice above 82%, and Hausdorff distance below 15 mm.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA verification and validation covered non-ML outputs and machine-learning modules. Validation used 235 anonymized patient images with component-specific counts: 70 coronary, 102 calcium, 63 SAX function, 63 each for 2-, 3-, and 4-chamber LAX function, and 252 function-classification samples. Reported ranges were 97%-100% series classification, 7%-10% SAX and 5%-9% LAX volumetric MAE, 86%-99% calcium classification, 82%-94% coronary centerline performance, and 98%-100% coronary-mask performance. Cardiac CT segmentation reported LV MAE below 10%, Dice above 86%, Hausdorff distance below 9.5 mm, and EF bias 1.3% (95% CI -12 to 14); RV MAE below 18%, Dice above 85%, Hausdorff distance below 18 mm, and EF bias -5.5% (95% CI -15 to 4.4); LV-myocardium MAE below 17%, Dice above 82%, and Hausdorff distance below 15 mm.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

cvi42 Software Application regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K242781
  • Samplen=235
  • IndependenceIndependence not established

K242781

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K242781. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Previously acquired cardiovascular MR and CT images in DICOM format from cardiovascular MR or CT scanners; the packet limits analysis to cardiac images and states that the machine-learning modules are intended for adults.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K242781: cvi42 Software Application

  2. Routing

    Source context, not route validation: Accepts uploaded DICOM data and does not interface directly with acquisition equipment; results are available on screen and can be saved. The FDA packet describes stand-alone or networked use and DICOM compliance but does not establish a specific PACS, RIS, EHR, or local interface version.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K242781: cvi42 Software Application

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 ·

  4. Returned objects

    Source context, not route validation: Display and reconstruction tools plus measurements including distance, area, volume, mass, signal intensity, Agatston score, stenosis, velocity, strain, cardiac function metrics, and semi-automatic cardiac segmentation; also calcium scoring, coronary centerline analysis, vessel stenosis evaluation, lesion reporting, and key images.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K242781: cvi42 Software Application

  5. Viewer/worklist/report

    Unresolved route: Display and reconstruction tools plus measurements including distance, area, volume, mass, signal intensity, Agatston score, stenosis, velocity, strain, cardiac function metrics, and semi-automatic cardiac segmentation; also calcium scoring, coronary centerline analysis, vessel stenosis evaluation, lesion reporting, and key images.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K242781: cvi42 Software Application

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Accepts uploaded DICOM data and does not interface directly with acquisition equipment; results are available on screen and can be saved. The FDA packet describes stand-alone or networked use and DICOM compliance but does not establish a specific PACS, RIS, EHR, or local interface version.
  • Exact FDA submission
  • Checked 2026-09-08
Security
Circle Cardiovascular Imaging's cvi42 page (dated 2026-05-05) states that cvi42 processes imaging data entirely within the customer's environment (hospital workstation or customer-managed server) with no data transmitted outside the institution; that the AI models are locked, frozen and encrypted when integrated into cvi42 and do not continue to learn once deployed; and that the AI does not learn from or store customer-site patient data. Vendor statement; no certification or test report was read.
  • Product family
  • Checked 2026-10-26

Vendor statement, not an attestation. The page is on circlecvi.com and describes cvi42 without naming a version, so it is family-level context.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for cvi42 Software Application; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K242781
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA; MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Cardiovascular system; heart, coronary and adjacent vessels, and cardiac valves
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-10-15
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K242781 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K242781: cvi42 Software Application

    U.S. Food and Drug Administration - Published 2024-10-15 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. cvi42 Software Application model card (K242781)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K242781

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. Circle Cardiovascular Imaging: How AI Works in cvi42 - Secure, Smart, and Fully Local

    Circle Cardiovascular Imaging - Published 2026-05-05 - Accessed 2026-10-26

    Scope: security

Research history

  1. K242781 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K213998

cvi42 Auto Imaging Software Application

Circle Cardiovascular Imaging Inc

Authorized purpose: Viewing, post-processing, qualitative and quantitative evaluation, cardiac measurements, calcium scoring, and evaluation of physician-identified vascular lesions in cardiovascular MR/CT images.

Modality
CT/CTA; MRI
Anatomy
Heart and adjacent cardiovascular vessels
Decision
2022-07-28
FDA-cleared K192437

Arterys MICA

Arterys Inc.

Authorized purpose: Support-tool image processing for quantitative cardiovascular assessment and oncologic lesion evaluation, quantification, follow-up, and documentation to aid trained healthcare professionals in diagnosis; the software does not directly generate a diagnosis or potential findings.

Modality
CT/CTA; MRI
Anatomy
Heart and major vessels for Cardio AI; oncology lesion anatomy is not further specified in the FDA statement.
Decision
2020-03-25
FDA-cleared K182034

Arterys MICA

Arterys Inc.

Authorized purpose: DICOM/non-DICOM image and data management with optional quantitative cardiac MR and oncology lesion evaluation, quantification, follow-up, and documentation support; the software does not directly generate a diagnosis or potential findings.

Modality
CT/CTA; MRI
Anatomy
Heart and major vessels for the optional Cardio AI module; lung and liver lesions or nodules for the optional Oncology AI module; the base viewer handles broader radiological image data.
Decision
2018-10-17
FDA-cleared K231683

inHEART Models

inHEART, SAS

Authorized purpose: Create, review, analyze, annotate, export, and use 3D cardiac models to support reading, reporting, and therapeutic-intervention planning.

Modality
CT/CTA; MRI
Anatomy
Cardiac structures, including the aorta, atria, ventricles, pulmonary artery trunk, and right atrium/inferior vena cava structures described in the FDA performance table
Decision
2024-02-29

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history